¼¼°èÀÇ ¿©¼º ÇコÄÉ¾î ½ÃÀå
»óǰÄÚµå : 1795228
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 189 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,245,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,736,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¿©¼º ÇコÄÉ¾î ¼¼°è ½ÃÀåÀº 2030³â±îÁö 121¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 97¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¿©¼º ÇコÄÉ¾î ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 3.8%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 121¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀΠȣ¸£¸ó¼º ºÒÀÓ ¿ëµµ´Â CAGR 3.4%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 31¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Æó°æÈÄ °ñ´Ù°øÁõ ÀÀ¿ë ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 2.6%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 26¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 6.8%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¿©¼º ÇコÄÉ¾î ½ÃÀåÀº 2024³â¿¡ 26¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2024³âºÎÅÍ 2030³â ºÐ¼® ±â°£ µ¿¾È CAGR 6.8%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 24¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 1.5%¿Í 2.8%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 2.1%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¿©¼º ÇコÄÉ¾î ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¿Ö ¿©¼º ÇコÄɾ ¼¼°è º¸°Ç ºÐ¾ß¿¡¼­ µÎµå·¯Áø ¿ì¼±¼øÀ§ ºÐ¾ß·Î ºÎ»óÇϰí ÀÖ´Â °ÍÀϱî?

¿©¼º ÇコÄɾî´Â ±¤¹üÀ§ÇÑ ÇコÄÉ¾î »ýÅÂ°è ³»¿¡¼­ Àü¹® ¿µ¿ªÀ¸·Î ºü¸£°Ô ÁøÈ­Çϰí ÀÖ½À´Ï´Ù. ÀÌ´Â ¿©¼ºÀº »ý¾ÖÁֱ⺰·Î »ý¸®Àû, È£¸£¸óÀû, »ý½ÄÀû °Ç°­ ¿ä±¸°¡ ´Ù¸£´Ù´Â ÀνÄÀÌ È®»êµÇ°í ÀÖÀ½À» ¹Ý¿µÇÕ´Ï´Ù. ³²³à¸¦ ºÒ¹®Çϰí ÀϹÝÀûÀÎ Ä¡·á¸¦ ÇÏ´Â °æ¿ì°¡ ¸¹¾Ò´ø ±âÁ¸ÀÇ ÇコÄÉ¾î ¸ðµ¨°ú ´Þ¸®, Çö´ë ÀÇ·á¿¡¼­´Â ¼ºº°¿¡ ƯȭµÈ Áø´Ü, Ä¡·á, ¿¹¹æ ÀÇ·áÀÇ Á߿伺ÀÌ Á¡Á¡ ´õ ¸¹ÀÌ Àνĵǰí ÀÖ½À´Ï´Ù. ¿©¼ºÀÇ °Ç°­ÀÌ ¿ì¼±¼øÀ§¿¡ ³õÀÌ°Ô µÈ ¹è°æ¿¡´Â Àӻ󿬱¸¿¡¼­ ¿©¼ºÀÇ ºñÀ²ÀÌ ³·°í Á¦µµÀûÀ¸·Î ¿©¼ºÀº °æ½ÃµÇ¾î ¿Â ¿ª»ç°¡ ÀÖÀ¸¸ç, ÀÌ´Â ¿©¼º ȯÀÚÀÇ ¿ÀÁøÀ̳ª ÃÖÀûÀÇ Ä¡·á°¡ ÀÌ·ç¾îÁöÁö ¾Ê´Â °á°ú·Î À̾îÁ® ¿Ô½À´Ï´Ù. ¿À´Ã³¯ Á¤ºÎ, ÀÇ·á ¼­ºñ½º Á¦°øÀÚ ¹× ¼¼°è Á¶Á÷Àº ¿ù°æ °Ç°­, ºÒÀÓ, ÀÓ½Å, Æó°æ, À¯¹æ¾Ï, ºÎÀΰú ¾Ï, °ñ´Ù°øÁõ, ÀÚ°¡ ¸é¿ª Áúȯ µî¿¡ ÃÊÁ¡À» ¸ÂÃá ¼­ºñ½º¸¦ Á¶Á¤ÇÏ¿© ÀÌ·¯ÇÑ °ÝÂ÷¸¦ ÇØ¼ÒÇÏ´Â µ¥ ´õ ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖ½À´Ï´Ù. »çȸ¿îµ¿°ú ¿ËȣȰµ¿À¸·Î Àڱ󻸷Áõ, »êÈÄ ¿ì¿ïÁõ, ÇÇÀӱⱸ Á¢±Ù¼º µîÀÇ ¹®Á¦°¡ ÁÖ¸ñ¹ÞÀ¸¸ç Á¤Ã¥ ´ëÀÀ°ú ÀÚ±Ý ¹èºÐ °³¼±ÀÌ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Àü ¼¼°è ¿©¼ºÀÇ °í·ÉÈ­·Î ÀÎÇØ ½ÉÇ÷°ü °Ç°­, °ñ¹Ðµµ, È£¸£¸ó Á¶Àý°ú °ü·ÃµÈ ¸¸¼ºÁúȯ °ü¸®¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÇ·á°è´Â ¿©¼ºÀÇ °Ç°­°ü¸® ¿ä±¸°¡ »ý½Ä ÀÇ·á¿¡ ±¹ÇѵÇÁö ¾Ê´Â´Ù´Â °ÍÀ» ÀνÄÇϰí, ¸ðµç ¿¬·É°ú ¹è°æÀ» °¡Áø ¿©¼º¿¡°Ô ½Ã±âÀûÀýÇϰí Á¤È®ÇÏ¸ç ¼ºÀÎÁöÀû °üÁ¡ÀÇ Áø·á¸¦ º¸ÀåÇÏ´Â º¸´Ù Æ÷°ýÀûÀÌ°í °øÆòÇÑ ½Ã½ºÅÛÀ» °³¹ßÇϱâ À§ÇÑ ¹ß°ÉÀ½À» ³»µó°í ÀÖ½À´Ï´Ù.

±â¼ú Çõ½ÅÀº ¿©¼º °Ç°­ °ü¸®¿¡ ¾î¶² Çõ¸íÀ» °¡Á®¿À°í Àִ°¡?

±â¼úÀº ¿©¼º ÀÇ·á ȯ°æÀ» À籸¼ºÇϰí, ÀÇ·á ¼­ºñ½º¸¦ º¸´Ù °³ÀÎÈ­, Á¢±Ù¼º, µ¥ÀÌÅÍ Áß½ÉÈ­, µ¥ÀÌÅÍ ±â¹ÝÈ­ ÇÏ´Â µ¥ ÀÖ¾î Çõ½ÅÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. °¡Àå ¿µÇâ·Â ÀÖ´Â ¹ßÀü Áß Çϳª´Â ¸ð¹ÙÀÏ ¾Û, ¿þ¾î·¯ºí ±â±â, ¿ø°Ý °Ç°­ Ç÷§Æû°ú °°Àº µðÁöÅÐ °Ç°­ µµ±¸ÀÇ º¸±ÞÀ¸·Î, ¿©¼ºµéÀÌ Áý¿¡¼­ »ý¸® ÁÖ±â ÃßÀû, ÀӽаúÁ¤ ¸ð´ÏÅ͸µ, ÇÇÀÓ Á¶¾ð, ¸¸¼ºÁúȯ °ü¸® µîÀ» ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. °ü¸®ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¹è¶õ ÃßÀû±â, AI¸¦ ÀÌ¿ëÇÑ Ã¼¿Ü¼öÁ¤(IVF) Ç÷§Æû µî ºÒÀÓ Ä¡·á ±â¼úÀº ¿©¼º¿¡°Ô »ý½Ä ŸÀÓ¶óÀÎÀ» º¸´Ù ÀÚÀ¯·Ó°Ô ÅëÁ¦ÇÒ ¼ö ÀÖ´Â ±ÇÇÑÀ» ºÎ¿©Çϰí ÀÖ½À´Ï´Ù. Áø´Ü ±â¼úµµ Çâ»óµÇ¾î °íµµÀÇ ¿µ»ó Áø´Ü°ú À¯ÀüÀÚ °Ë»ç·Î À¯¹æ¾Ï, ³­¼Ò¾Ï µîÀÇ Áúº´À» Á¶±â¿¡ ¹ß°ßÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¿ø°ÝÁø·á´Â ¿©¼ºµéÀÌ À̵¿, ³«ÀÎ, °¡±î¿î °÷¿¡ Àü¹®Àǰ¡ ¾ø´Ù´Â µîÀÇ À庮¿¡ Á÷¸éÇÏ´Â °æ¿ì°¡ ¸¹À¸¸ç, ƯÈ÷ ³óÃÌ Áö¿ªÀ̳ª ÀÇ·á ¼­ºñ½º°¡ ºÎÁ·ÇÑ Áö¿ª¿¡¼­´Â ¿ø°ÝÁø·á°¡ ƯÈ÷ Áß¿äÇÕ´Ï´Ù. ¶ÇÇÑ, ÀüÀÚÀǹ«±â·Ï°ú ¿¹Ãø ºÐ¼®Àº ÀÓ»óÀǰ¡ °³º° ȯÀÚ ÇÁ·ÎÇÊ¿¡ µû¶ó Ä¡·á °èȹÀ» Á¶Á¤ÇÏ¿© È£¸£¸ó Ä¡·á ¹× »ê¸ð °ü¸®¿Í °°Àº ºÐ¾ßÀÇ °á°ú¸¦ °³¼±ÇÏ´Â µ¥ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù. ½ºÅ¸Æ®¾÷°ú ÆèÅ×Å© ±â¾÷µéÀº ¿©¼º ƯÀ¯ÀÇ ´ÏÁî¿¡ ƯȭµÈ ºñħ½ÀÀû Áø´Ü, µðÁöÅÐ °ñ¹ÝÀú±ÙÀ° Æ®·¹À̳Ê, Á¤½Å°Ç°­ Ç÷§Æû µî Çõ½ÅÀûÀÎ ¼Ö·ç¼ÇÀ» °³¹ßÇϸç ÁÖµµ±ÇÀ» Áã°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Çõ½ÅÀº ÀÓ»ó Ä¡·á¸¦ °³¼±ÇÒ »Ó¸¸ ¾Æ´Ï¶ó ¿À·£ ±Ý±â¸¦ ±ú°í °Ç°­¿¡ ´ëÇÑ ±ÇÇÑ ºÎ¿© ¹®È­¸¦ ÃËÁøÇÏ¿© ¿©¼ºµéÀÌ ±× ¾î´À ¶§º¸´Ù ½±°í Àڽۨ ÀÖ°Ô ÀÚ½ÅÀÇ °Ç°­¿¡ Àû±ØÀûÀÎ ¿ªÇÒÀ» ÇÒ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù.

¿©¼º ÇコÄÉ¾î ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â »çȸÀû º¯È­¿Í Á¤Ã¥ °³ÇõÀº?

»çȸÀû Àνİú Á¤Ã¥ °³ÇõÀº ¿©¼º ÇコÄÉ¾î ½ÃÀåÀÇ ¹æÇâ°ú ¸ð¸àÅÒÀ» Çü¼ºÇÏ´Â µ¥ ÀÖ¾î Á¡Á¡ ´õ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î ¿©¼ºµéÀº ¾çÁúÀÇ ÀÇ·á ¼­ºñ½º¿¡ ´ëÇÑ ´õ ³ªÀº Á¢±Ù¼º, ÀÓ»ó ¿¬±¸¿¡¼­ÀÇ µ¿µîÇÑ ´ëÇ¥¼º, °Ç°­ ºÒÆòµî¿¡ ´ëÇÑ ´õ °­·ÂÇÑ º¸È£¸¦ ¿ä±¸Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ´õ °­·ÂÇÑ »çȸÀû ´ã·Ð°ú ÀÔ¹ý Á¶Ä¡·Î À̾îÁö°í ÀÖ½À´Ï´Ù. Á¤ºÎ¿Í º¸°Ç ±â°üÀº »ê¸ð °ü¸®, ºÒÀÓ Ä¡·á, ÇÇÀÓ, ¾Ï °ËÁø¿¡ ´ëÇÑ º¸Àå ¹üÀ§¸¦ È®´ëÇÏ´Â Á¤Ã¥À» Á¦Á¤Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ´ëºÎºÐ ±¤¹üÀ§ÇÑ ¾ç¼º Æòµî°ú º¸ÆíÀû °Ç°­ °ü¸®ÀÇ Æ² ¾È¿¡¼­ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ¿ù°æ °øÆò¼ºÀ» µÑ·¯½Ñ Àü ¼¼°èÀûÀÎ È­µÎ´Â »ý¸®´ë ¹«·á Á¦°ø, »ý¸® °ü·Ã Æí°ß ÇØ¼Ò¸¦ À§ÇÑ ±³À°, »ý¸®¿ëǰ ¹«·á Á¦°ø µîÀ» ÀÇ·á±â°ü¿¡ Ã˱¸Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ »êÈÄ ¿ì¿ïÁõ, ºÒ¾ÈÀå¾Ö µî ¿©¼ºÀÇ Á¤½Å°Ç°­ ¹®Á¦°¡ °¡½ÃÈ­µÇ¸é¼­ º¸´Ù Æ÷°ýÀûÀ̰í ÅëÇÕÀûÀÎ Á¤½Å°Ç°­ ¼­ºñ½º·ÎÀÇ ÀüȯÀÌ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù. º¸Çè»çµéµµ ´õ ³ªÀº ¿¹¹æ Ä¡·á¿Í Àå±âÀûÀÎ À£ºù ¼Ö·ç¼Ç¿¡ ´ëÇÑ ½ÃÀåÀÇ ¿ä±¸¸¦ ¹Ý¿µÇÏ¿© º¸´Ù Á¾ÇÕÀûÀÎ ¿©¼º °Ç°­ °ü·Ã ÇýÅÃÀ» Æ÷ÇÔÇϱ⠽ÃÀÛÇß½À´Ï´Ù. ´Ù³¶¼º³­¼ÒÁõÈıº(PCOS), ÀڱñÙÁ¾, Æó°æ µî ¸¸¼ºÀûÀ̸鼭µµ °ú¼Ò Áø´ÜµÈ ÁúȯÀÇ ¿µÇâÀ» ¹Þ´Â »ç¶÷µéÀÇ ¸ñ¼Ò¸®´Â ¹Ìµð¾î¿Í ¿ËÈ£ Ä·ÆäÀÎÀ» ÅëÇØ Áö¼ÓÀûÀ¸·Î ÁõÆøµÇ°í ÀÖÀ¸¸ç, ÀÇ·á°è´Â ¿¬±¸¿Í ±³À°¿¡ ÅõÀÚÇÒ °ÍÀ» Ã˱¸Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ »çȸÀû, ±ÔÁ¦Àû ÀüȯÀº ÀÇ·á¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» °³¼±ÇÒ »Ó¸¸ ¾Æ´Ï¶ó ¿©¼ºÀÇ °Ç°­À» µÑ·¯½Ñ ¹®È­Àû À̾߱⸦ À籸¼ºÇϰí, ¿©¼ºÀÇ ÀÇÇÐÀû °ü½É»ç°¡ Ÿ´çÇϸç Á¦µµÀû Áö¿øÀ» ¹ÞÀ» °¡Ä¡°¡ ÀÖÀ½À» È®ÀνÃÄÑÁÝ´Ï´Ù. ±× °á°ú, Á¤º¸¿¡ Á¤ÅëÇϰí, Âü¿©Çϸç, ÈûÀ» °¡Áø ȯÀÚÃþÀÌ ´Ã¾î³ª°í ÀÖÀ¸¸ç, ÀÇ·á ½Ã½ºÅÛÀÌ ±×µéÀÇ ¿ä±¸¿¡ ¸ÂÃç ÁøÈ­Çϱ⸦ ±â´ëÇÏ°Ô µÇ¾ú½À´Ï´Ù.

¼¼°è ¿©¼º ÇコÄÉ¾î ½ÃÀåÀÇ ¼ºÀå ¿øµ¿·Â°ú Àå±âÀû ÀáÀç·ÂÀº ¹«¾ùÀϱî?

¿©¼º ÇコÄÉ¾î ½ÃÀåÀÇ ¼ºÀåÀº Àα¸Åë°èÇÐÀû, ±â¼úÀû, ±â¼úÀû, °æÁ¦Àû, »çȸÁ¤Ä¡Àû ¿äÀÎÀÌ º¹ÇÕÀûÀ¸·Î ÀÛ¿ëÇϰí ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ ¿äÀεéÀÌ °áÇÕÇÏ¿© ¼ºº°¿¡ ƯȭµÈ ÇコÄÉ¾î ¼Ö·ç¼Ç¿¡ ´ëÇÑ ÅõÀÚÀÇ Á߿伺°ú ½Ã±Þ¼ºÀ» °­Á¶Çϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä ÃËÁø¿äÀÎ Áß Çϳª´Â Àü ¼¼°è ¿©¼º Àα¸ÀÇ Áõ°¡¿Í Æò±Õ ¼ö¸íÀÇ Áõ°¡·Î ÀÎÇØ ³ëÈ­, È£¸£¸ó º¯È­, ¸¸¼ºÁúȯ °ü¸®¿Í °ü·ÃµÈ Àå±â¿ä¾ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ¿©¼ºÀÇ °æÁ¦Àû ¿ª·® °­È­¿Í ±³À° ¼öÁØ Çâ»óµµ ¿¹¹æÀû ÀÇ·á¿Í ¸ÂÃãÇü Ä¡·á ¿É¼ÇÀ» Àû±ØÀûÀ¸·Î Ãß±¸Çϰí, °Ç°­ °ü·Ã Áö½ÄÀÌ Ç³ºÎÇÑ ¼ÒºñÀÚÃþ Çü¼º¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ºÒÀÓ Áø´Ü¿¡¼­ ¿ø°ÝÀÇ·á Ç÷§Æû¿¡ À̸£±â±îÁö ÀÇ·á ±â¼úÀÇ °¡¿ë¼º°ú °¡°Ý »ó½ÂÀº ƯÈ÷ ÀÇ·á ÀÎÇÁ¶ó°¡ ºü¸£°Ô °³¼±µÇ°í ÀÖ´Â ½ÅÈï±¹¿¡¼­ Á¢±Ù¼ºÀ» È®´ëÇϰí Á¶±â °³ÀÔÀ» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. º¥Ã³ ijÇÇÅÐÀÇ ÆèÅ×Å© ¹× ¿©¼º Á᫐ °Ç°­ ½ºÅ¸Æ®¾÷¿¡ ´ëÇÑ ÅõÀÚ´Â ½ÃÀå¿¡ Çõ½ÅÀ» ºÒ·¯ÀÏÀ¸Å°°í, ¿ª»çÀûÀ¸·Î ¼Ò¿ÜµÈ ºÐ¾ß¿¡ ´ëÇÑ ´ëÀÀÀ» µ½°í ÀÖ½À´Ï´Ù. ÀÌ¿Í ÇÔ²² ´Ù±¹Àû Á¦¾à»çµéÀº È£¸£¸ó ¿ä¹ýºÎÅÍ Ç¥Àû ¾Ï Ä¡·á±îÁö ¿©¼º¿¡°Ô ¿µÇâÀ» ¹ÌÄ¡´Â Áõ»ó¿¡ ¸ÂÃá »õ·Î¿î Ä¡·áÁ¦¸¦ Ãâ½ÃÇϰí ÀÖ½À´Ï´Ù. ±ÔÁ¦ ´ç±¹µµ ÀÌ¿¡ ¹ß¸ÂÃç ¿©¼º Àü¿ë ÀǾàǰ ¹× ÀÇ·á±â±âÀÇ ½ÂÀÎ °æ·Î¸¦ °£¼ÒÈ­ÇÏ¿© ½ÃÀå °³Ã´À» ´õ¿í °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ±â¾÷ÀÇ À£´Ï½º ÇÁ·Î±×·¥°ú Á÷Àå ³» °Ç°­ ÇÁ·Î±×·¥µµ ¿©¼º ƯÀ¯ÀÇ °Ç°­ ¹®Á¦¸¦ ÀνÄÇϰí À̸¦ ÇØ°áÇÔÀ¸·Î½á ´õ ³ªÀº °Ç°­ °á°ú¿Í »ý»ê¼ºÀ» ÃËÁøÇϱ⠽ÃÀÛÇß½À´Ï´Ù. ÀÌ·¯ÇÑ »óÈ£ ¿¬°üµÈ ¿øµ¿·ÂÀº ÇコÄÉ¾î ºÐ¾ßÀÇ ¼ºº° °ÝÂ÷ ÇØ¼Ò¸¦ À§ÇÑ Áö¼ÓÀûÀÎ ³ë·ÂÀ» ¹Ý¿µÇϸç, ¿©¼º¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ °ü½É°ú ¿¬±¸, ±×¸®°í ÀÇ·á ¹ßÀüÀÌ ÀÌ·ç¾îÁú ¼ö ÀÖµµ·Ï ÇÏ´Â ¿øµ¿·ÂÀÌ µÉ °ÍÀÔ´Ï´Ù. ¿©¼º °Ç°­ ÁõÁøÀÌ °¡Á·, Áö¿ª»çȸ, °æÁ¦ÀÇ ÇູÀÇ Åä´ë¶ó´Â ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ¿©¼º ÇコÄÉ¾î ½ÃÀåÀº Àü ¼¼°èÀûÀ¸·Î °è¼Ó È®´ëµÇ°í ÀÖ½À´Ï´Ù.

ºÎ¹®

¿ëµµ(È£¸£¸ó¼º ºÒÀÓ ¿ëµµ, Æó°æÈÄ °ñ´Ù°øÁõ ¿ëµµ, Àڱ󻸷Áõ ¿ëµµ, ÇÇÀÓ ¿ëµµ, °»³â±â ¿ëµµ, ´Ù³¶¼º³­¼ÒÁõÈıº ¿ëµµ, ±âŸ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Women's Healthcare Market to Reach US$12.1 Billion by 2030

The global market for Women's Healthcare estimated at US$9.7 Billion in the year 2024, is expected to reach US$12.1 Billion by 2030, growing at a CAGR of 3.8% over the analysis period 2024-2030. Hormonal Infertility Application, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$3.1 Billion by the end of the analysis period. Growth in the Postmenopausal Osteoporosis Application segment is estimated at 2.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.6 Billion While China is Forecast to Grow at 6.8% CAGR

The Women's Healthcare market in the U.S. is estimated at US$2.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.4 Billion by the year 2030 trailing a CAGR of 6.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Global Women’s Healthcare Market - Key Trends & Drivers Summarized

Why Is Women’s Healthcare Emerging as a Distinct and Prioritized Sector in Global Health?

Women’s healthcare is rapidly evolving as a specialized domain within the broader healthcare ecosystem, reflecting the growing awareness that women have unique physiological, hormonal, and reproductive health needs across different life stages. Unlike traditional healthcare models that often generalized treatments for both genders, modern medicine increasingly recognizes the importance of gender-specific diagnostics, treatments, and preventive care. The prioritization of women’s health stems from a history of underrepresentation in clinical research and systemic neglect, which has led to misdiagnoses and suboptimal care for female patients. Today, governments, healthcare providers, and global organizations are placing a stronger emphasis on addressing these disparities by tailoring services that focus on menstrual health, fertility, pregnancy, menopause, breast and gynecological cancers, osteoporosis, and autoimmune diseases, among others. Social movements and advocacy efforts have brought attention to issues like endometriosis, postpartum depression, and contraceptive access, prompting better policy responses and funding allocation. In addition, an aging female population worldwide is increasing demand for chronic disease management related to cardiovascular health, bone density, and hormone regulation. By recognizing that women’s healthcare needs extend far beyond reproductive care, the medical community is taking steps to develop a more comprehensive and equitable system that ensures timely, accurate, and gender-sensitive care for women of all ages and backgrounds.

How Are Technological Innovations Revolutionizing the Women’s Healthcare Landscape?

Technology is playing a transformative role in reshaping the women’s healthcare landscape, making care more personalized, accessible, and data-driven. One of the most impactful developments is the proliferation of digital health tools such as mobile apps, wearable devices, and telehealth platforms that enable women to track their menstrual cycles, monitor pregnancy progress, access contraception advice, and manage chronic conditions from the comfort of their homes. Fertility tech, including ovulation trackers and AI-assisted in vitro fertilization (IVF) platforms, is empowering women with more control over their reproductive timelines. Diagnostic technologies have also improved, enabling earlier detection of diseases such as breast and ovarian cancer through advanced imaging and genetic testing. Remote consultations have become especially important in rural and underserved areas, where women often face barriers related to mobility, stigma, or lack of nearby specialists. In addition, electronic health records and predictive analytics are helping clinicians tailor treatment plans based on individual patient profiles, improving outcomes in areas like hormonal therapy and prenatal care. Startups and femtech companies are leading the charge by developing innovative solutions such as non-invasive diagnostics, digital pelvic floor trainers, and mental health platforms that cater specifically to women’s unique needs. These innovations are not only enhancing clinical care but also breaking down longstanding taboos and promoting a culture of health empowerment, allowing women to take an active role in their well-being with unprecedented ease and confidence.

What Societal Shifts and Policy Changes Are Influencing the Women’s Healthcare Market?

Societal awareness and policy reforms are playing an increasingly important role in shaping the direction and momentum of the women’s healthcare market. Around the world, women are demanding better access to quality healthcare, equal representation in clinical research, and stronger protections against health inequities, leading to more robust public discourse and legislative action. Governments and health agencies are enacting policies to expand coverage for maternal care, fertility treatments, contraception, and cancer screenings, often under broader gender equality or universal healthcare frameworks. The global conversation around menstrual equity is prompting institutions to provide free sanitary products and education, helping dismantle the stigma that surrounds menstruation. Additionally, the rising visibility of women’s mental health challenges, including postpartum depression and anxiety disorders, is prompting a shift toward more inclusive and integrated mental healthcare services. Insurance providers are also beginning to include more comprehensive women’s health benefits, reflecting market demand for better preventive care and long-term wellness solutions. Media and advocacy campaigns continue to amplify the voices of those affected by chronic yet underdiagnosed conditions such as polycystic ovary syndrome (PCOS), fibroids, and perimenopause symptoms, prompting the medical community to invest in research and education. These societal and regulatory shifts are not only improving access to care but also reshaping cultural narratives around female health, affirming that women’s medical concerns are both valid and deserving of systemic support. The result is a more informed, engaged, and empowered patient base that expects healthcare systems to evolve in step with their needs.

What Is Driving the Global Growth and Long-Term Potential of the Women’s Healthcare Market?

The growth in the women’s healthcare market is driven by a confluence of demographic, technological, economic, and sociopolitical factors that together underscore the importance and urgency of investing in gender-specific health solutions. One of the primary drivers is the rising global female population coupled with increased life expectancy, which is resulting in higher demand for long-term care related to aging, hormonal changes, and chronic illness management. Economic empowerment and higher educational attainment among women are also contributing to a more health-literate consumer base that actively seeks preventive care and personalized treatment options. The increasing availability and affordability of health technologies, from fertility diagnostics to telemedicine platforms, are expanding access and enabling earlier interventions, particularly in emerging economies where healthcare infrastructure is improving rapidly. Venture capital investment in femtech and women-centric health startups is infusing the market with innovation and helping address historically neglected areas. In parallel, multinational pharmaceutical companies are launching new therapeutics tailored to conditions affecting women, from hormone therapies to targeted cancer treatments. Regulatory bodies are responding by streamlining approval pathways for female-specific drugs and devices, further accelerating market development. Corporate wellness programs and workplace health initiatives are also beginning to recognize and address women’s unique health challenges, fostering better health outcomes and productivity. These interconnected drivers reflect a sustained commitment to closing the gender gap in healthcare, ensuring that women receive the attention, research, and medical advancements long overdue. The trajectory of the women’s healthcare market points toward continued global expansion, supported by a growing awareness that empowering women’s health is foundational to the well-being of families, communities, and economies.

SCOPE OF STUDY:

The report analyzes the Women's Healthcare market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Application (Hormonal Infertility Application, Postmenopausal Osteoporosis Application, Endometriosis Application, Contraceptives Application, Menopause Application, Polycystic Ovary Syndrome Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â